Gentamicin and tobramycin pharmacokinetics in pediatric bone marrow transplant patients

Annals of Pharmacotherapy

Volumn 31, Issue 10, 1997, Pages 1127-1131

  Jacobson, Pamala A ^a   West, Nina J ^a   Price, Jessica ^b   Hutchinson, Raymond J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b CHILDREN S HOSPITAL   (United States)

Author keywords

Bone marrow transplant; Gentamicin; Tobramycin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BUSULFAN; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GENTAMICIN; IFOSFAMIDE; MELPHALAN; THIOTEPA; TOBRAMYCIN;

ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; GRAFT VERSUS HOST REACTION; HUMAN; PEDIATRICS; PRIORITY JOURNAL;

EID: 0030964644     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703101002     Document Type: Article

References (21)

1. McAllister TA. Gentamicin in paediatrics. Postgrad Med J 1974;50(suppl 7):45-52.
2. Haghbin M, Armstrong D, Murphy ML. Intravenous gentamicin for infectious complications in children with acute leukemia. J Infect Dis 1971;124:(suppl):s192-7.
3. Siber GR, Echeverria P, Smith AL, Paisley JW, Smith DH. Pharmacokinetics of gentamicin in children and adults. J Infect Dis 1975;132:637-51.
4. Langley J, Gold R. Sepsis in febrile neutropenic children with cancer. Pediatr Infect Dis J 1988;7:34-7.
5. Ho KK, Bryson SM, Thiessen JJ, Greenberg ML, Einarson TR, Leson CL. The effects of age and chemotherapy on gentamicin pharmacokinetics and dosing in pediatric oncology patients. Pharmacotherapy 1995;15: 754-64.
6. Zeitany RG, El Saghir NS, Santhosh-Kumar CR, Sigmon MA. Increased aminoglycoside dosage requirements in hematologic malignancy. Antimicrob Agents Chemother 1990;34:702-8.
7. Hall P, Koeller R, Miles R, et al. A prospective pharmacokinetic evaluation of aminoglycosides in 104 cancer patients (abstract). Proc Annu Meet Am Soc Clin Oncol 1989;8:A1327.
8. Phillips JK, Spearing RL, Crome DJ, Davies JM. Gentamicin volumes of distribution in patients with hematologic disorders (letter). N Engl J Med 1988;319:1290.
9. Higa GM, Murray WE. Alterations in aminoglycoside pharmacokinetics in patients with cancer. Clin Pharm 1987;6:963-6.
10. Hoecker JL, Pickering LK, Swaney J, Kramer WG, van Eys J, Feldman S, et al. Clinical pharmacology of tobramycin in children. J Infect Dis 1978;137:592-6.
11. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984;149:443-8.
12. Harriet Lane handbook. 14th ed. St. Louis, MO: Mosby Year Book, 1996.
13. Ticarcillin monograph. Drugdex. Englewood, CO: Micromedex, 1997.
14. Jolley ME, Stroupe SD, Schwenzer KS, Wang CJ, Lu-Steffes M, Hill HD, et al. Fluorescence polarization immunoassay III. An automated system for therapeutic drug determination. Clin Chem 1981;27:1575-9.
15. Sawchuk RJ, Zaske DE, Cipolle RJ, Wargin WA, Strate RG. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther 1976;21:362-9.
16. Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976;58:259-63.
17. Shull BC, Haughey D, Koup JR, Balish T, Li PK. A useful method for predicting creatinine clearance in children. Clin Chem 1978;24:1167-9.
18. Bianco TM, Dwyer PN, Bertino JS. Gentamicin pharmacokinetics, nephrotoxicity, and prediction of mortality in febrile neutropenic patients. Antimicrob Agents Chemother 1989;33:1890-5.
19. Manny RP, Hutson PR. Aminoglycoside volume of distribution in hematology-oncology patients (letter). Clin Pharm 1986;5:629-30.
20. Davis RL, Lehmann D, Stidley CA, Neidhart J. Amikacin pharmacokinetics in patients receiving high dose cancer chemotherapy. Antimicrob Agents Chemother 1991;35:944-7.
21. Kramer WG, Cleary T, Frankel LS, Kohl S, Pickering LK. Multiple-dose amikacin kinetics in pediatric oncology patients. Clin Pharmacol Ther 1979;26:635-40.